ATE367167T1 - Aufbereitung von aldesleukin zur pharmazeutischen verwendung - Google Patents

Aufbereitung von aldesleukin zur pharmazeutischen verwendung

Info

Publication number
ATE367167T1
ATE367167T1 AT05250680T AT05250680T ATE367167T1 AT E367167 T1 ATE367167 T1 AT E367167T1 AT 05250680 T AT05250680 T AT 05250680T AT 05250680 T AT05250680 T AT 05250680T AT E367167 T1 ATE367167 T1 AT E367167T1
Authority
AT
Austria
Prior art keywords
aldesleukin
sds
pharmaceutical use
preparation
give
Prior art date
Application number
AT05250680T
Other languages
English (en)
Inventor
Maninder Hora
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE367167T1 publication Critical patent/ATE367167T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05250680T 2005-02-07 2005-02-07 Aufbereitung von aldesleukin zur pharmazeutischen verwendung ATE367167T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05250680A EP1688146B1 (de) 2005-02-07 2005-02-07 Aufbereitung von Aldesleukin zur pharmazeutischen Verwendung

Publications (1)

Publication Number Publication Date
ATE367167T1 true ATE367167T1 (de) 2007-08-15

Family

ID=34940439

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05250680T ATE367167T1 (de) 2005-02-07 2005-02-07 Aufbereitung von aldesleukin zur pharmazeutischen verwendung

Country Status (10)

Country Link
EP (1) EP1688146B1 (de)
AT (1) ATE367167T1 (de)
CY (1) CY1108521T1 (de)
DE (1) DE602005001688T2 (de)
DK (1) DK1688146T3 (de)
ES (1) ES2289663T3 (de)
HR (1) HRP20070487T3 (de)
PL (1) PL1688146T3 (de)
PT (1) PT1688146E (de)
SI (1) SI1688146T1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010134091A1 (en) * 2009-05-20 2010-11-25 M/S. Provimi Animal Nutrition India Private Limited A process for preparation of a non-antibiotic growth promoter formula / product and its use in food animals
HUE054318T2 (hu) * 2010-11-12 2021-08-30 Nektar Therapeutics IL-2 molekularész konjugátumai és polimer
EP2925297B1 (de) 2012-11-02 2017-06-21 CyTuVax Zusammensetzung enthaltend zytokin makroaggregate
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
AU2016341241B9 (en) * 2015-10-22 2021-11-18 Iltoo Pharma Pharmaceutical compositions of IL-2
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
EP3630813A1 (de) 2017-05-24 2020-04-08 Novartis AG Antikörper-zytokin- gepfropfte proteine und verfahren zur verwendung in der krebsbehandlung
SG11202012299SA (en) * 2018-06-13 2021-01-28 Akron Biotechnology Llc Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions
US11517685B2 (en) 2019-01-18 2022-12-06 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
US11690963B2 (en) 2018-08-22 2023-07-04 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2

Also Published As

Publication number Publication date
DK1688146T3 (da) 2007-11-05
DE602005001688T2 (de) 2008-04-10
CY1108521T1 (el) 2014-04-09
SI1688146T1 (sl) 2007-12-31
PL1688146T3 (pl) 2007-12-31
DE602005001688D1 (de) 2007-08-30
EP1688146B1 (de) 2007-07-18
HRP20070487T3 (en) 2007-12-31
PT1688146E (pt) 2007-10-29
EP1688146A1 (de) 2006-08-09
ES2289663T3 (es) 2008-02-01

Similar Documents

Publication Publication Date Title
ATE367167T1 (de) Aufbereitung von aldesleukin zur pharmazeutischen verwendung
DE602006016735D1 (de) Verfahren zur proliferation von stammzellen
DE602006017732D1 (de) Verfahren zur herstellung von lyophilisiertem piperacillin-natrium in kombination mit tazobactam-natrium, mit verbesserter stabilität nach der rekonstitution
CO6210752A2 (es) Compuestos biciclicos y uso como antidiabeticos
DE102005001078A8 (de) Glaspulver, insbesondere biologisch aktives Glaspulver und Verfahren zur Herstellung von Glaspulver, insbesondere biologisch aktivem Glaspulver
DE602005018981D1 (de) Verfahren zur Herstellung von L-Cystein, und L-Cystein-produzierender Mikroorganismus
GB2441939A (en) Surgical membrane
HK1123733A1 (en) Viral hepatitis treatment
TW200700092A (en) Tigecycline compositions and methods of preparation
EA201791850A1 (ru) Борсодержащие малые молекулы
EA200701707A1 (ru) Пиразолопиримидины
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation
BRPI0721984B8 (pt) interferon-2b peguilado (ifn-2b), seu método de preparo e de purificação, composição, bem como uso dos mesmos
ATE551381T1 (de) Verfahren zur herstellung von hochkonzentrierte pelletierte additivkonzentrate für polymer
DE602005016282D1 (de) Verfahren zur herstellung von camptothecin-derivaten
MX2023004078A (es) Proteinas f de hmpv estabilizadas por prefusion.
ATE385252T1 (de) Verfahren zur herstellung von granulatförmigen zusammensetzungen
ATE410443T1 (de) Heterocyclyl-substituierte nonadepsipeptide
ATE464289T1 (de) Neues verfahren zur herstellung von thoc
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
DE502006007928D1 (de) Feste salzzubereitung, deren herstellung und verwendung
ATE451109T1 (de) Medizinische lösung; verfahren zur herstellung dieser lösung und ihre verwendung
DE602004002692D1 (de) Verfahren zur Herstellung von Topiramate
ATE420168T1 (de) Verfahren zur herstellung von extrachromosomalen nukleinsäuremolekülen
DE602005018941D1 (de) Verwendung von winterbohnenkraut (satureja montana) oder seinen extrakten zur herstellung von medikamenten zur behandlung von vorzeitiger ejakulation